CUMULATIVE COST OF TREATMENT WITH ILUVIEN (FLUOCINOLONE ACETONIDE [FAC]) VERSUS THE CURRENT STANDARD OF CARE IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN PHAKIC EYES OVER A 3 YEAR PERIOD- AN ANALYSIS ...
Author(s)
Quhill F1, Beiderbeck A2
1Royal Hallamshire Hospita, Sheffield, UK, 2Alimera Sciences Ophthalmologie GmbH, Berlin, Germany
Presentation Documents
INTRODUCTION: ILUVIEN is an intravitreal implant that releases 0.2 μg of FAc per day for up to 36 months with a single injection. In the UK, NICE TA301 recommends it as an option for treating chronic DMO that is insufficiently responsive to available therapies in eyes that are pseudophakic; however, the FAME trial showed efficacy outcomes were not affected by lens status. OBJECTIVES: Assess the budgetary impact of switching 30 phakic eyes from the current standard of care, assuming they had an insufficient response to an anti-VEGF, to ILUVIEN (FAc implant). METHODS: A budget-impact model was developed in phakic lenses and over a single dosing cycle for the FAc implant. Local hospital patient data was entered for the current prescribing pattern for ranibizumab (7 injections in year 1; 4 in year 2 and 3 in year 3). This was compared with the cost of a change to the FAc implant with an assumption that 50% of eyes would receive additional ranibizumab once per year over a 3 year period. The model takes into account the cost of monitoring patients and managing adverse events. RESULTS:
The scenarios modelled projected a total saving of £119,655 over a single dosing cycle for the FAc implant. Savings were observed in every year, with the greatest savings from switching to the FAc implant observed in year 2
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PSS16
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Sensory System Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now